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The effects of mold sensitivity on the clinical characteristics  
of adult asthmatic patients
Abstract
Introduction: The effects of mold sensitivity on the development and course of asthma have been researched previously, although 
study results vary. We sought to evaluate the characteristics of our mold-sensitive patients in comparison with those of other 
adult asthmatic patients. 
Materials and methods: Data were collected retrospectively from adult asthmatic patients who underwent regular follow-ups at 
our tertiary care outpatient clinic for immunology and allergic diseases. Patients were grouped and compared according to three 
categories of aeroallergen sensitivity status determined via a skin prick test. The study variables were demographic data, asth-
ma-onset age, comorbid conditions, asthma-related emergency department visits and hospitalizations, systemic corticosteroid 
burst, asthma control assessment tests, and pulmonary function tests. 
Results: In total, 242 patients’ data were evaluated. Their mean age was 48.6 ± 15.4 years, with female predominance (81.4%). 
Mold-sensitive asthmatics composed 34.7%, while the aeroallergen-sensitive group without molds (33.1%) and the non-sensitized 
group (32.2%) composed the rest. The mold-sensitive group had a higher rate of polysensitization (92.8%) than the sensitized 
group without molds. In multinomial logistic regression analysis, mold sensitivity was positively associated with shorter asthma 
duration, absence of sinonasal polyposis, presence of allergic rhinitis, and generally well-controlled asthma compared to the 
non-sensitized group. Also, mold sensitivity was positively associated with shorter asthma duration, drug allergy, and absence of 
systemic corticosteroid bursts compared to the sensitized group without molds in logistic regression analysis. 
Conclusion: Our mold-sensitive asthmatic patients demonstrated better asthma symptom control. It should be considered that 
mold sensitization in adult asthmatics is not always a poor prognostic factor.
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Introduction
Asthma is a heterogeneous disease, usually 
characterized by chronic airway inflammation 
[1]. There are many factors that have a role in 
the development and control of asthma [1]. Mold 
exposure and sensitization to molds constitute 
a significant trigger factor. Mold sensitizations 
and their role in asthma have been previously 
evaluated in many studies [2]. Most of these inve-
stigations have found that mold sensitivity has an 
effect not only on the development of asthma, but 
also in the success of asthma control efforts and 
the severity of asthma [2] by way of inducing type 
I allergic reactions in susceptible individuals [3].
Direct associations between increased fungal 
exposure and a loss of asthma control are nu-
merous [4]. Previous studies have suggested an 
increased risk of asthma development after mold 
exposure at an early age [2, 5]. McSharry et al. 
found that high environmental mold exposure 
was associated with poor lung function [6]. Be-
sides the impact on asthma development, fungal 
sensitization was also found to have an effect on 
the persistence and activation of asthma symp-
toms, and on the severity of asthma [2, 7]. 
Mold species including Penicillium, Aspergill­
us and Cladosporium have been studied in con-
junction with asthma. Alternaria species have 
been found to increase the risk of asthma symp-
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tom exacerbation [8]. In previous research, sensi-
tization to Alternaria and Cladosporium had been 
associated with severe asthma [4]. The European 
Community Respiratory Health Survey also 
showed that Alternaria and Cladosporium were 
significantly associated with asthma severity [9]. 
In one study, patients admitted to the intensive 
care unit for a severe asthma attack were found 
to have a positive skin prick test for A. alternata 
and C. herbarum [10].
Notably, climate change has been labelled as 
a potential contributing factor in aeroallergens 
due to the risk of accelerated mold sporulation 
in environments with increased CO2 [11, 12]. 
The effects of the existing climate on fungal 
sensitization also impact characteristics of va-
rious aeroallergens, including mold sporulation 
patterns [11, 12]. Turkey’s diverse regions have 
significantly different climates because of the 
country’s irregular topography. For example, the 
coastal areas of Turkey bordering the Black Sea 
have a temperate oceanic climate with warm, wet 
summers and cool-to-cold, wet winters. The Tur-
kish Black Sea coast is the only region of Turkey 
that receives such high precipitation throughout 
the year. Thus, inhabitants in this region face the 
possibility of indoor and outdoor mold exposure 
throughout the year more so than their neighbors. 
The effects of mold sensitization have been 
thoroughly reported in severe asthmatics [2]; 
however, in general asthmatic patients, the link 
is not as definite. Although mold sensitization 
and asthma outcomes are generally associated 
with poor prognoses [2], research from various 
geographical areas has indicated the opposite 
[13]. Therefore, in this study, we sought to explore 
the percentage and pattern of mold sensitization 
among adult asthmatics and to reveal the simila-
rities and/or differences between mold-sensitized 
asthmatics and non-sensitized patients. To our 
knowledge, this study is the first to evaluate the 
clinical characteristics of adult asthmatics accor-
ding to their mold sensitivity status in Turkey.
Materials and methods
Study design
A retrospective case–control study was conduct-
ed after obtaining local ethics committee approval on 
June 20, 2018 (approval no. 40465587-120).
Setting and participants
Patients meeting relevant criteria who were 
admitted to the department of immunology and 
allergic diseases in the outpatient clinic between 
June 2013 and June 2018, and having an asthma 
diagnosis according to Global Initiative for Asthma 
(GINA) guidelines [1] were retrospectively evalu-
ated from their paper files. The hospital has elec-
tronic records for all patients. In this department, 
doctors also collected and filed separate paper files 
for each patient. These files contained demograph-
ic characteristics, past medical history, comorbid 
conditions, anamnesis regarding asthma-related 
admissions, and patient symptoms. Laboratory 
data, skin prick test (SPT) and acceptable pulmo-
nary function test (PFT) results of the patients were 
also recorded to that file by the doctors, along with 
records of follow-up evaluations. In the follow-ups, 
which were made at 3 or 6 month intervals, pa-
tients were questioned about symptoms, exacer-
bations, and all prescribed medications. Physical 
examinations and required test results, such as 
PFT, were also recorded at that time. 
All data regarding the allergic status of pa-
tients was pulled from tests administered in our 
hospital. Previous records or patients’ anamnesis 
regarding allergic diseases were confirmed by test 
results. In patients with symptoms of allergic rhi-
nitis (AR), the diagnosis was confirmed by nasal 
endoscopic examination by ear-nose-throat ex-
perts, regardless of patient SPT results. Sinonasal 
polyposis (SNP) diagnoses were also confirmed 
by nasal endoscopic examination.
Among all relevant patients, 242 adult asth-
matics met the inclusion criteria and were there-
fore included in this study. Inclusion criteria 
were as follows: asthmatics older than 18 years 
of age who participated in regular follow-up vis-
its at least once a year who had SPT results and 
acceptable PFT results (14). Exclusion criteria 
were being younger than 18 years of age, having 
irregular follow-ups or follow-up periods being 
under a year, missing patient file information, and 
patients who had respiratory comorbidities such 
as bronchiectasis and/or allergic bronchopulmo-
nary aspergillosis, among others. 
Data collection
Patients’ demographics, smoking history, 
body mass index (BMI), asthma history, asthma 
duration, age at asthma diagnosis, comorbidities, 
presence of allergic rhinitis, sinonasal polyposis, 
drug allergies, systemic corticosteroid use, and 
lifetime hospitalization/emergency department 
visits were obtained from manually filled records. 
PFT and SPT results performed concurrently on 
the same day were recorded.
Records of SPTs were obtained from patient 
follow-up records. For each patient, an SPT had 
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been performed involving common inhalant aller-
gens including Dermatophagoides pteronyssinus 
and Dermatophagoides farinae (dust mites); As­
pergillus, Alternaria, Cladosporium, and Penicil­
lium (molds); cat and dog dander; latex; pollens 
from grass, trees, and weeds; and cockroaches 
(Allergopharma, Reinbek, Germany). SPTs were 
performed on the volar forearm and were read 
after 20 minutes. A wheal reaction with a mean 
diameter of 3 mm greater than the negative con-
trol was considered to indicate allergen positivity. 
PFT was performed according to recom-
mendations (14) using a pulmonary spirometer 
(CareFusion, Germany, 234 GmbH). The best of 
three attempts was recorded. Postbronchodila-
tor forced expiratory volume in the first second 
(FEV1), forced vital capacity (FVC), and forced 
expiratory flow at 25–75% of FVC (FEF25–75) values 
were obtained from the study participants’ files. 
Our procedures for SPT and PFT are thoroughly 
described in our previous studies’ methods sec-
tion [14, 15].
For evaluating asthma symptom control, the 
GINA assessment of asthma control in adults was 
used [1, 15].
Statistical analysis 
Patients were grouped into three categories 
according to SPT results: non-sensitized patients, 
sensitized patients without molds, and sensitized 
patients with molds (Figure 1). 
For data analysis, the Statistical Package for 
the Social Sciences version 22 (IBM Corp., Ar-
monk, NY, USA) was used. Categorical variables 
are expressed as absolute and relative frequencies, 
whereas quantitative variables are expressed as 
means and standard deviations. To evaluate the 
relationship between independent variables (i.e. 
demographic variables, asthma history, asthma 
clinical course, and PFT) and dependent variables, 
Pearson’s chi-squared test was used. For categor-
ical variables and numerical variables, one-way 
analysis of a variance test was used with a post-
hoc Tukey test. Associations were considered 
significant at p < 0.05. Multinomial logistic regres-
sion was used to find differences among the three 
groups. A multivariate logistic regression analysis 
was performed by the backward likelihood ratio 
test to find differences between the mold-sensitive 
group and the sensitized group without molds. 
Results
In total, 242 adult asthmatic patients’ data 
were evaluated. The mean age of the study partic-
ipants was 48.6 ± 15.4 years. Most study subjects 
were female (81.4%), homemakers (68.6%), had 
never smoked (81.8%), had comorbid diseases 
(56.6%), had AR (81.4%), and were on less than 
five medications for asthma (81.4%) (Table 1).
Figure shows the sensitization patterns of pa-
tients according to SPTs. Out of 242, the non-sen-
sitized patient rate was 32.2%. Of them, 33.1% had 
aeroallergen sensitivity without molds, 30.2% had 
mold sensitivity plus at least one other aeroallergen 
sensitivity, and 4.5% had only mold sensitivity. 
Therefore, most of the patients in the mold-sensitive 
group were also sensitized to other aeroallergens.
Figure 1. Aeroallergen sensitization pattern of the patients
Nonsensitive 
78 (32.2%)
73 
(30.2%)
80
(33.1%)
Aeroallergen 
sensitivity with 
molds 
84
11
(4.5%)
Aeroallergen sensitivity 
without molds 
153 
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Table 1. Demographic characteristics of patients and comparison of them among groups
Variables Total
(242)
SPT negative
(n = 78, 32.2%)
SPT positivity 
without mold  
sensitization
(n = 80, 33.1%)
SPT positivity with 
mold sensitization  
(n = 84, 34.7%)
Age (mean ± SD) 48.6 ± 15.4 59.9 ± 14.1#¶ 45.8 ± 14.9 44.5 ± 14.7
Gender  
    Female
    Male
197 (81.4)
45 (18.6)
65 (33.0)
13 (28.9)
64 (32.5)
16 (35.6)
68 (34.5)
16 (35.6)
Job**
    Housewife
    Occupational risk
    No occupational risk
166 (68.6)
52 (21.5)
24 (9.9)
63 (38.0)*
3 (12.5)
12 (23.1)
49 (29.5)
13 (54.2)
18 (34.6)
54 (32.5)
8 (33.3)
22 (42.3)
Smoking status
    Non-smoker
    Former smoker
    Current smoker
198 (81.8)
22 (9.1)
22 (9.1)
65 (32.8)
9 (40.9)
4 (18.2)
64 (32.3)
9 (40.9)
7 (31.8)
69 (34.8)
4 (18.2)
11 (50.0)
Smoking (pack/year) 3.69 ± 8.4 3.37 ± 7.71 4.75 ± 10.5 3.1 ± 7.1
BMI (kg/m2) 30.0 ± 6.4 32.1 ± 7.5#¶ 29.5 ± 5.4 28.6 ± 5.6
Comorbid disease  
    Present
    Absent
137 (56.6)
105 (43.4)
52 (38.0)#
26 (24.8)
48 (35.0)#
32 (30.5)
37 (27.0)
47 (44.8)
AR               
    Present
    Absent
197 (81.4)
45 (18.6)
52 (26.4)#¶
26 (57.8)
68 (34.5)
12 (26.7)
77 (39.1)
7 (15.6)
SNP             
    Present
    Absent
36 (14.9)
206 (85.1)
18 (50.0)#
60 (29.1)
11 (30.6)
69 (33.5)
7 (19.4)
77 (37.4)
Drug allergy      
    Present
    Absent
18 (7.4)
224 (92.6)
10 (55.6)¶
68 (30.4)
2 (11.1)
78 (34.8)
6 (33.3)
78 (34.8)
Number of medications used for asthma 
and/or rhinitis symptoms
    ≥ 5 [n%]
    ≤ 4 [n%]
    Mean (± SD)
45 (18.6)
197 (81.4)
2.93 ± 1.32
9 (20.0)#¶
69 (35.0)
2.74 ± 1.19
22 (48.9)
58 (29.4)
3.20 ± 1.42
14 (31.1)
70 (35.5)
2.85 ± 1.30
Omalizumab use
    Present
    Absent
21 (8.7)
221 (91.3)
5 (23.8)***
73 (33.0)
9 (42.9)
71 (32.1)
7 (33.3)
77 (34.8)
FEV1% 88.0 ± 13.8 86.4 ± 15.3¶ 94.3 ± 16.0 90.0 ± 14.9
FEV25–75 68.3 ± 30.1 64.2 ± 30.2 74.0 ± 28.9 71.1 ± 30.6
FEV1/FVC 76.4 ± 8.77 75.5 ± 9.99 76.9 ± 7.82 77.0 ± 9.45
#Compared to the group that had have prick test positivity with mold sensitization; ¶Compared to the group that had prick test positivity without mold sensitization; 
*Among housewives, normal prick test was significantly higher than the group with occupational risk, Patients that have jobs with occupational risk factor; *, #, ¶Show 
the statistical significance between groups, p < 0.05; **Job was classified according to presence of occupational risk factors for asthma; ***5 patients who used 
omalizumab and had a negative skin prick test were found to have specific IgE positivitiy for perennial allergens.
AR — allergic rhinitis; BMI — body mass index; FEV1 — forced expiratory volume in first second; FEF25-75 — forced vital capacity and forced expiratory flow at 25–75% 
of forced vital capacity; SPT — skin prick test
Table 2 shows data relating to the asthma 
characteristics of the included patients. The 
mean age at asthma diagnosis was 39.3 ± 15.2, 
and 50.4% of patients were younger than 40 years 
of age at the time of asthma onset. The majority 
of patients had experienced no hospitalization 
(80.6%), no emergency department admission 
(63.6%), and had no systemic steroid (SS) use 
(71.1%) during their disease course. According 
to GINA Asthma Control Test scores, most pa-
tients had “well-controlled” asthma (59.9%); the 
rest had either “partially controlled” (20.2%) or 
“uncontrolled” asthma (20.2%).
When considering aeroallergen sensitization 
patterns, 32.2% of our adult asthmatic patients 
were non-sensitized, 33.1% had sensitivity to 
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Table 2. Comparison of patients’ characteristics according to asthma course
Variables Total
(242)
SPT negative
 (n = 78, 32.2%)
SPT positivity 
without mold  
sensitization 
(n = 80, 33.1%)
SPT positivity with 
mold sensitization  
(n = 84, 34.7%)
Asthma diagnosis age (years) 39.3±15.2 44.9 ± 14.5#¶ 36.1 ± 15.6 37.3 ± 14.1
Asthma onset age
    < 40 [n%]
    ≥ 40 [n%]
122 (50.4)
120 (49.6)
28 (23.0)#¶
50 (41.7)
47 (38.5)
33 (27.5)
47 (38.5)
37 (30.8)
Asthma duration (years) 9.36 ± 8.9 11.2 ± 10.9# 9.7 ± 8.5 7.3 ± 6.7
Lifetime hospitalization due to asthma   
    Present
    Absent
    Mean ( ± SD)
47 (19.4)
195 (80.6)
0.77 ± 2.7
23 (48.9)#
55 (28.2)
1.53 ± 4.26#¶
14 (29.8)
66 (33.8)
0.34 ± 1.06
10 (21.3)
74 (37.9)
0.49 ± 1.76
Emergency department visits 
    Present [n%]
    Absent [n%]
    Mean ( ± SD)
88 (36.4)
154 (63.6)
2.68 ± 6.52
38 (43.2)#¶
40 (26.0)
4.33 ± 9.7¶
25 (28.4)
55 (35.7)
1.8 ± 3.73
25 (28.4)
59 (38.3)
1.99 ± 4.33
Systemic steroid use
    Present [n%]
    Absent [n%]
    Mean ( ± SD)
70 (28.9)
172 (71.1)
1.76 ± 5.28
29 (41.4)#
49 (28.5)
2.55 ± 7.53
25 (35.7) 
55 (32.0)
1.71 ± 4.45
16 (22.9)
68 (39.5)
1.07 ± 2.87
Asthma control status
    Well controlled    
    Partially controlled
    Uncontrolled
144 (59.5)
49 (20.2)
49 (20.2)
43 (29.9) 
18 (36.7)
17 (34.7)
50 (34.7)
17 (34.7)
13 (26.5)
51 (35.4)
14 (28.6)
19 (38.8)
Note: R2 = 0.31 (Cox–Snell), 0.35 (Nagelkerke). Model c2 = 91.122, p < 0.0001; goodness of fit; deviance-p = 0.402; pearson-p = 0.183. #Compared to the group 
that had have prick test positivity with mold sensitization; ¶Compared to the group that had prick test positivity without mold sensitization. SPT — skin prick test
aeroallergens without molds, and 34.7% demon-
strated mold sensitivity with or without other 
common aeroallergens. While those with mold 
sensitivity were mostly polysensitized (60.9%), 
those without mold sensitivity were mostly 
mono-sensitized (83.3%; p < 0.05). Identified 
sensitized mold species included Cladosporium 
(48.2%), Aspergillus (43.4%), Penicillium (38.6%), 
and Alternaria (21.7%).
In univariate analysis, the mean age and 
mean BMI of non-sensitized patients were higher 
than those of the sensitized groups (p < 0.05). In 
addition, the number of patients with a high num-
ber of medications used (5 or more medications) 
was lower in the non-sensitized group. The pres-
ences of comorbidities, SNP, and drug allergies 
were also higher among non-sensitized patients. 
The mean FEV1% was lower in the non-sensitized 
group, compared with sensitized patients without 
mold sensitization (p < 0.05) (Table 1).
Furthermore, univariate analysis revealed 
that the mean age of asthma diagnosis, prevalence 
of late-onset asthma (≥ 40 years), mean number 
of hospitalizations, and number of patients who 
experienced emergency department (ED) admis-
sion were higher in the non-sensitized group (p 
< 0.05). Finally, asthma duration and presence 
of SS bursts were higher in the non-sensitized 
group when compared with the mold-sensitive 
group (p < 0.05) (Table 2).
Table 3 shows the multinomial logistic re-
gression analysis findings of other groups in 
comparison with the non-sensitized group. The 
absence of drug allergies [odds ratio (OR): 8.794, 
95% confidence interval (CI): 1.499–51.603], 
absence of ED admission (OR: 3.351, 95% CI: 
1.116–10.065), and presence of occupational ex-
posure (OR: 7.943 CI: 1.383–45.608) were more 
associated with sensitization without molds as 
compared to patients with non-sensitization. Sep-
arately, shorter asthma duration (OR: 1.795, 95% 
CI: 0.829–3.890), absence of SNP (OR: 3.791, CI: 
1.207–11.903), presence of AR (OR: 4.132, 95% 
CI: 1.436–11.886), and well-controlled asthma 
(OR: 2.647, CI: 1.096–6.392) were more associated 
with mold sensitivity than with non-sensitization.
Table 4 shows the differences identified 
between mold-sensitive patients and sensitized 
patients without following logistic regression 
analysis. Shorter asthma duration (OR:2.170, 
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Table 3. Associations between groups compared to nonsensitive group in multinominal analysis
SPT positivity without  
mold sensitization  
SPT positivity with  
mold sensitization  
Gender (male gender compared to female) 3.534 (0.914–13.672) 2.997 (0.782–11.488)
Age group (< 65 vs ≥ 65) 1.294 (0.444–0.637) 2.511 (0.756–8.348)
Asthma duration (shorter than 10 years vs longer than 10 years) 0.977 (0.461–2.068) 1.795 (0.829–3.890)*
Asthma onset age (< 40 age vs ≥ 40 age) 1.633 (0.717–3.720) 1.135 (0.497–2.595)
BMI (< 30 vs ≥ 30) 1.228 (0.564–2.675) 1.581 (0.706–3.541)
Comorbidity (presence vs absence) 1.004 (0.436–2.315) 0.523 (0.224–1.221)
SNP (absence vs presence) 1.972 (0.707–5.501) 3.791 (1.207–11.903)*
AR (presence vs absence) 2.036 (0.818–5.068) 4.132 (1.436–11.886)*
Drug allergy (absence vs presence) 8.794 (1.499–51.603)* 1.293 (0.347–4.825)
Hospitalization (absence vs presence) 2.071 (0.705–6.080) 2.746 (0.900–8.372)
Emergency admission (absence vs presence) 3.351 (1.116–10.065)* 1.758 (0.636–4.858)
Systemic steroid burst (absence vs presence) 2.747 (0.858–8.793) 0.686 (0.222–2.114)
Omalizumab use (presence vs absence) 3.348 (0.766–14.631) 3.610 (0.808–16.129)
Asthma control (well controlled vs other) 1.219 (0.511–2.912) 2.647 (1.096–6.392)*
Number of medications using for asthma and/or rhinitis symptoms (≥ 5 vs ≤ 4) 1.944 (0.734–5.153) 1.048 (0.366–2.999)
Job
    Housewife
    No occupational risk group
    Occupational risk group
1
2.722 (0.866–8.555)
7.943 (1.383–45.608)*
1
1.918 (0.607–6.066)
3.899 (0.667–22.787)
Smoking status
    Never smoker
    Former smoker
    Current smoker
1
0.673 (0.184–2.459)
0.863 (0.186–4.008)
1
0.299 (0.065–1.369)
1.461 (0.0355–6.018)
FEV1% predicted (< 80 vs ≥ 80) 0.260 (0.651–1.628) 1.019 (0.419–2.478)
Note: R2 = 0.31 (Cox–Snell); 0.35 (Nagelkerke). Model c2 = 91.122, p < 0.0001; goodness of fit; deviance-p = 0.402; pearson-p = 0.183. *p < 0.05, shows the 
statistically significant difference. BMI — body mass index; FEV1 — forced expiratory volume in first second; SPT — skin prick test
95% CI: 1.028–4.583), presence of drug allergy 
(OR:7.462, 95% CI:1.053–52.887), and absence 
of SS (OR:3.647, 95% CI:1.108–12.006) were 
more associated with the mold-sensitive group 
in comparison to the sensitized group without 
mold-sensitization.
Discussion
This study revealed that nearly one-third of 
adult asthmatic patients treated at this clinic are 
mold-sensitive; most of that group have poly-
sensitization but well-controlled asthma. When 
compared with the non-sensitized group, patients 
in the mold-sensitive group were positively asso-
ciated with shorter asthma duration, the presence 
of AR, an absence of SNP, and the presence of 
well-controlled asthma. Additionally, mold sensi-
tivity was positively associated with the presence 
of drug allergies and an absence of SS bursts in 
comparison with sensitized patients without 
mold-sensitivity. In this study, we evaluated our 
population using two models. Firstly, univariate 
analysis was used to compare the three groups 
(non-sensitized, sensitized without molds, and 
sensitized with molds). Secondly, a multivariate 
analysis and logistic regression analysis of factors 
associated with mold sensitivity, in comparison 
with other groups, were performed. Due to the ex-
istence of confounding variables, we will discuss 
our findings according to the results of the logistic 
regression analysis, but also consider univariate 
analysis results in our comments.
The relationship between mold sensitivity 
status and asthma has been previously studied. 
Many prior studies showed that mold had a neg-
ative impact on asthma symptoms and asthma 
control [2]. A recent study that evaluated the 
relationship between mold burden in house dust 
and asthma control found that the concentrations 
of some molds detected in dust samples from the 
homes of asthma patients were negatively associ-
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Table 4.  Factors associated with mold sensitivity compa-
red to non-mold sensitive group
Mold sensitive group
Gender (female vs male) 1.026 (0.304–3.466)
Age groups (< 65 vs ≥ 65 age) 1.728 (0.413–7.221)
Asthma duration  
(< 10 vs ≥ 10 years) 
2.170 (1.028–4.583)*
Asthma onset age  
(≥ 40 vs < 40 years) 
1.421 (0.634–3.182)
BMI (< 30 vs > 30 kg/m2) 1.327 (0.597–2.950)
Comorbidity (absence vs presence) 1.992 (0.868–4.576)
SNP (absence vs presence) 1.716 (0.469–6.275)
AR (presence vs absence) 2.096 (0.623–7.058)
Drug allergy (presence vs absence) 7.462(1.053–52.887)*
Hospitalization (absence  
vs presence)
1.489 (0.455–4.876)
Emergency admission  
(presence vs absence)
1.587 (0.533–4.717)
Systemic steroid use  
(absence vs presence)
3.647(1.108–12.006)*
Omalizumab (absence vs presence) 1.086(0.292–4.041)
Asthma control (others vs well con-
trolled) 
2.513 (1.086–5.816)
Number of medications used for 
asthma and/or rhinitis symptoms  
(≤ 5 vs ≥ 5)
2.126 (0.878–5.164)
Job           
    Occupational risk group
    No occupational risk group
    Housewife
1
1.588 (0.419–6.028)
1.878 (0.460–7.665)
Smoking status          
    Never smoker
    Current smoker
    Former smoker
1
1.720 (0.484–6.119)
0.592 (0.147–2.379)
FEV1% predicted (< 80 vs ≥ 80) 1.380 (0.551–3.459)
Note: R2(Cox–Snell: 0.174, Nagelkerke:0.233) model p < 0.05. *p < 0.05, 
shows the statistically significant difference.
AR — allergic rhinitis; BMI — body mass index; FEV1 — forced expiratory 
volume in first second; SPT — skin prick test
ated with parameters of asthma control in male 
subjects, but not in female ones. The researchers 
attributed their finding to males demonstrating 
a stronger immunoglobulin (Ig) E response follow-
ing exposure to some molds. This speculation was 
also supported by the higher IgE concentrations 
of males in population studies and the higher 
capability of males to produce stronger allergic 
responses to fungal infections. Also, potentially 
due to the protective effects of sex hormones, 
women were expected to have a stronger immune 
response than that of men [7]. In our study, only 
18.6% of our study population was male. The 
fact that the majority of our study population was 
female may be one of the explanations for finding 
a reverse relationship between mold sensitivity 
and asthma control. In another study from China, 
mold-sensitive asthmatics appeared to have 
higher asthma severity scores than those of the 
sensitized group without mold-sensitization, 
but they had lower FEV1 values than those of the 
non-sensitized group [16]. These authors, how-
ever, excluded asthmatics with smoking histories; 
all of their participants were nonsmokers. In this 
study, our findings showed a positive impact 
on patients’ asthma control status as well as SS 
bursts. We included asthmatics who smoke, but 
neither the univariate nor multivariate results 
differed with respect to smoking status.
In a cohort study, the effects of mold or 
dampness exposure during infancy on the risk of 
asthma, rhinitis, or IgE sensitization was evaluat-
ed in children followed from birth to 16 years of 
age. During this investigation, sensitization was 
assessed using blood samples in 3,293 children. 
Exposure to any mold or dampness was associat-
ed with asthma in patients up to 16 years of age, 
while exposure to mold odor and visible mold 
were associated with rhinitis. Increased risks 
were observed for nonallergic asthma and rhinitis 
[17]. Considering this study, it is possible that 
mold exposure also adversely affects nonallergic/ 
/nonatopic asthmatics rather than only mold-sen-
sitive cases. In our study, data on environmental 
mold exposure could not be measured due to the 
experimental design; therefore, this confounding 
factor should be considered in future research.
In a recent review article [2], the authors 
considered studies that measured mold exposure 
both by qualitative and quantitative methods in 
order to evaluate the association between asthma, 
asthma development, asthma exacerbation, and 
rhinitis. Exposure to molds by using a qualitative 
metrics approach (i.e. observation of visible mold 
or smell) was found to have an association with 
asthma development. In the same review, it is also 
mentioned that there is currently insufficient evi-
dence to determine whether an association exists 
between quantitatively measured mold species/ 
/components and the occurrence of asthma. In our 
study, we did not evaluate the indoor or outdoor 
mold exposure status of our study population. 
This is because it was previously reported that, re-
gardless of sensitization patterns, asthma control 
was worse in a high-mold exposure group [18]. 
There are other dissenting studies in the lit-
erature to consider when analyzing the findings 
of this study. Al-Ahmad et al. did not find molds 
to have a significant triggering role, despite the 
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high rate of sensitization leading to asthma exac-
erbation in the desert environment. These authors 
evaluated asthma exacerbations and mold concen-
trations across the four seasons and found a higher 
average concentration of Alternaria and Cladospo­
rium during September and November. Among 
the asthmatic participants, the mold-sensitive 
patients had higher rates of asthma exacerbations 
in that season. They additionally suggested that 
the climate and season can affect the presence of 
molds and asthma exacerbation [19]. Our region, 
the Eastern Black Sea of Turkey, has an oceanic 
climate with a narrow annual temperature range. 
This makes indoor mold growth and the outdoor 
mold rate similar during all four seasons. 
Based on our findings, it is obvious that 
the mold-sensitive patients had shorter asthma 
durations. Younger mean age and younger mean 
asthma diagnosis age, and thus a higher rate 
of early-onset asthma, were also determined 
in univariate analysis in the mold-sensitive 
group. Previous studies have suggested a link 
between new-onset asthma and mold exposure; 
prolonged exposure to molds was also found to 
have an effect on new-onset asthma [20]. Fur-
ther, it was concluded elsewhere that exposure 
to damp and moldy work places can induce 
new-onset adult asthma [21]. Mold exposure in 
early childhood was found to have an effect on 
asthma-related symptoms and the development 
of asthma at earlier ages [22]. Severe asthma with 
fungal sensitization was also found to be charac-
terized by an early onset of the disease [23]. The 
mold-sensitive patients’ shorter asthma durations 
and younger ages in this study could be related 
to the new-onset and early-onset effects of mold 
exposure in light of these prior investigations. 
However, Thacher et al. evaluated the effects of 
mold exposure on the development of asthma 
and rhinitis from birth to the age of 16 years in 
a cohort study and concluded that exposure to 
mold and dampness during infancy increased the 
odds of asthma and rhinitis. Further, exposure was 
associated with persistent asthma but not with 
early-transient or late-onset asthma [17]. 
The mold-sensitive group in our study had 
higher rates of AR. The effect of mold sensitivity 
on allergic rhinitis has been presented in previous 
studies [24]. Exposure to mold is associated with 
the development of asthma in occupants of damp 
buildings, and rhinitis is known to be a risk factor 
for asthma. However, there is little information 
about the degree of risk for the progression of 
rhinosinusitis to asthma owing to mold exposures 
in damp buildings [25]. Another study, from 
Poland, suggested AR patients’ clinical distinct-
ness. They found elevated nasal nitric oxide levels 
during seasons when the air concentrations of 
grass pollen and Alternaria spores were very high 
but there was no correlation during or after the 
pollen season [26]. The presence of a lower rate 
of SNP in our mold-sensitive group compared to 
the non-sensitized group is thus in line with the 
literature. It was previously reported that the SNP 
is more prevalent among nonatopic asthmatics 
than atopic asthmatics. Also, late-onset asthma 
was thought to have an association with the de-
velopment of nasal polyposis [27].
Strengths and limitations
This study allows us to compare asthma 
patients’ characteristics according to their mold 
sensitivity status, tested via SPT during their reg-
ular follow-ups. Data was gleaned from files from 
an expert ear-nose-throat outpatient clinic. Beside 
its ability to address a gap in the literature, there 
are some limitations that should be mentioned. 
The retrospective design of the study, as well as 
the heterogenous distribution of patients regarding 
gender and occupation, is a limiting factor. An-
other confounding factor is the sensitivity level of 
SPT, which limits the ability to determine the exact 
sensitization status of patients. Sensitivity of SPT 
in determining aeroallergen sensitization could be 
an issue. Therefore, future studies should consider 
using more specific tests. Of our patients, 5 who 
were treated with Omalizumab had negative SPT 
results. This may be due to steroid use or use of 
other medications that can produce false negative 
SPT results. Also, 26.4% of our asthmatics with an 
AR diagnosis had negative SPTs. In a previous na-
tional study, that rate was found to be 43.7% [28]. 
Evaluating all of the asthmatics that meet our broad 
inclusion criteria helped to make the groups more 
diverse. However, it also led to more confounding 
factors that could affect the evaluation of the direct 
effects of mold sensitivity. The lack of evaluation 
of indoor and outdoor mold exposure in the study 
design is another limiting factor.
In conclusion, asthmatic patients determined 
to be mold-sensitive by SPTs were found to have 
better asthma symptom control. The measure-
ment of the mold exposure that patients encoun-
ter in their unique environments can lead to better 
accuracy regarding the effects of mold on asthma 
control and comorbidities. Based on the findings 
of this study, it should be kept in mind that mold 
sensitization in adult asthmatics is not always 
a poor prognostic factor. 
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